Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
CELGENE CORPORATION v. NATCO PHARMA LIMITED
Case Number:
2:10-cv-05197
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
December 22, 2015
Celgene Allows Earlier Cancer Drug Generic In Patent Deal
Celgene Corp. has agreed to allow an India-based drugmaker to sell a generic version of its blood cancer treatment in the U.S. more than a year before the last-to-expire patent covering the drug runs out, as part of a settlement the companies reached Tuesday.
-
October 13, 2010
Celgene Sues Natco To Block Generic Revlimid
Celgene Corp. has slapped India's Natco Pharma Ltd. with a patent infringement lawsuit in an effort to keep a generic version of its top-selling drug Revlimid off the market.